When was MaaT Pharma founded?

MaaT Pharma was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is MaaT Pharma located?

MaaT Pharma is headquartered in Lyon, France.

How many employees does MaaT Pharma have?

As of Jun 30, 2026, the latest employee count at MaaT Pharma is 82.

Is MaaT Pharma a funded company?

MaaT Pharma is a funded company, having raised a total of $42.3M across 14 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 2014.

When was the latest funding round of MaaT Pharma?

MaaT Pharma's latest funding was a $***** Grant (prize money) round on Jul 20, 2021, with participation from 0 investor.

Where does MaaT Pharma rank among its competitors?

MaaT Pharma ranks 1st amongst 142 active competitors, of which 46 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was CERo Therapeutics, which secured $750K in May, 2026.

Who are the top competitors of MaaT Pharma?

MaaT Pharma's top competitors include Ossium Health, Rigel and Ajax. Among them, CERo Therapeutics secured the most recent funding round in May, 2026.

MaaT Pharma - 2026 Company Profile, Funding & Competitors

Company Details

Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases. The company develops the treatment using an autologous intestinal microbiota transplant. Its therapeutic applications are intended for patients suffering from malignant blood diseases or bone infections and taking heavy treatments fostering dysbiosis.

Website: www.maatpharma.com/
Social

Key Metrics

Founded Year

2014

Location

Lyon, France

Stage

Public

Total Funding

$42.3M in 14 rounds

Latest Funding Round

Grant (prize money), Jul 20, 2021, $*****

Investors

Bpifrance & 12 more

Ranked

1^st among 142 active competitors

Employee Count

82 as on Jun 30, 2026

Similar Companies

Ossium Health & 153 more

Exit Details

Public

View MaaT Pharma's full profile

MaaT Pharma got listed on Nov 08, 2021.

Click here to take a look at MaaT Pharma's IPO in detail

MaaT Pharma has raised a total funding of $42.3M over 14 rounds. Its first funding round was on Dec 2014. MaaT Pharma has 13 institutional investors.

Here is the list of recent funding rounds of MaaT Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 20, 2021	3347417	Grant (prize money)	5315241	6642077	9093332	5427623
Dec 01, 2020	7389145	Series B	5861987	6833916	3911243	Celeste Management & 1 more
Sep 01, 2020	4037077	Grant (prize money)	4857757	5951544	4425427	Europa

Access funding benchmarks and valuations. Sign up today!

View details of MaaT Pharma's funding rounds and investors

MaaT Pharma's employee count trend

MaaT Pharma has 82 employees as of Jun 26. Here is MaaT Pharma's employee count trend over the years:

Uncover MaaT Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MaaT Pharma include Ossium Health, Rigel and Ajax. Here is the list of Top 10 competitors of MaaT Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Bpifrance, SymBiosis & 11 others	65/100
2nd	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	General Catalyst, Vivo Capital & 12 others	65/100
3rd	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MPM Capital, MidCap Financial & 6 others	64/100
4th	Ajax 2019, Cambridge (United States), Acquired	Developer of targeted therapies for the treatment of hematologic malignancies	$135M	EcoR1, Goldman Sachs Asset Management & 8 others	64/100
5th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
6th	Adicet Bio 2014, Menlo Park (United States), Public	Developer of immune cell therapeutic solutions for the treatment of cancer	$51M	Consensus Business Group, Handok & 18 others	61/100
7th	GigaGen 2011, San Francisco (United States), Acquired	Developer of T-cell and antibody-based therapeutics	$36.1M	Claremont Creek Ventures, DOE & 5 others	59/100
8th	Kallyope 2014, New York City (United States), Series D	Discovering novel therapeutics for neurological and metabolic diseases	$479M	The Column Group, Illumina Ventures & 21 others	59/100
9th	CERo Therapeutics 2016, San Francisco (United States), Public	Developer of platforms for cellular immunotherapy	$54.8M	SRx Health, Arch Venture Partners & 1 others	58/100
10th	StemlineTherapeutics 2003, New York City (United States), Acquired	Oncology therapeutics innovator focused on transforming cancer patient lives	$15.1M	Avoro Capital, Great Point Partners & 1 others	58/100